- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Alembic Pharmaceuticals secured USFDA final approval for Bosutinib Tablets (100 mg and 500 mg), targeting the chronic myelogenous leukemia market valued at approximately US$ 291 million annually. This approval enhances Alembic’s US generics portfolio to 223 ANDA approvals, reinforcing its specialty oncology pipeline and supporting potential revenue growth in high-value cancer treatments.